Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Elomaa

Showing results (21-30 of 143) with videos related to

Pageof 15
Sort By:
Acta Rheumatologica Scandinavica|January 1, 1971
Muscle blood flow in rheumatoid arthritisM Oka, A Rekonen, I Elomaa
Acta Medica Scandinavica|January 1, 1984
Raynaud's phenomenon progressing to gangrene after vincristine and bleomycin therapyI Elomaa, M Pajunen, P Virkkunen
Breast Cancer Research and Treatment|January 1, 1986
Aminoglutethimide as second line therapy in advanced breast cancerI Elomaa, C Blomqvist, P Rissanen
Acta Medica Scandinavica|January 1, 1983
Amyloid-associated muscle pseudohypertrophy and multiple myeloma in a man with hypernephromaI Elomaa, P Ekblom, T Somer
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trialI Elomaa, H Joensuu, C Blomqvist
Duodecim; Laaketieteellinen Aikakauskirja|August 17, 2002
[Some light for the prognosis of gastric cancer]I Elomaa, M Kouri, T Kiviluoto
Annals of Medicine|April 1, 1992
Adjuvant hormone therapy in breast cancerC P Blomqvist, I Elomaa, P Rissanen
The Journal of Urology|October 1, 1984
Five years of experience with selective therapy in recurrent calcium nephrolithiasisI Elomaa, M Ala-Opas, L Porkka
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Testicular function after chemotherapy for osteosarcomaM A Siimes, I Elomaa, A Koskimies
British Journal of Cancer|August 1, 1992
Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myelomaI Elomaa, P Virkkunen, L Risteli, et al.
Pageof 15

Showing results (21-30 of 143) with videos related to

Sort By:
Pageof 15
Acta Rheumatologica Scandinavica|January 1, 1971
Muscle blood flow in rheumatoid arthritisM Oka, A Rekonen, I Elomaa
Acta Medica Scandinavica|January 1, 1984
Raynaud's phenomenon progressing to gangrene after vincristine and bleomycin therapyI Elomaa, M Pajunen, P Virkkunen
Breast Cancer Research and Treatment|January 1, 1986
Aminoglutethimide as second line therapy in advanced breast cancerI Elomaa, C Blomqvist, P Rissanen
Acta Medica Scandinavica|January 1, 1983
Amyloid-associated muscle pseudohypertrophy and multiple myeloma in a man with hypernephromaI Elomaa, P Ekblom, T Somer
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
Vinorelbine, methotrexate and fluorouracil (VMF) as first-line therapy in metastatic breast cancer: a randomized phase II trialI Elomaa, H Joensuu, C Blomqvist
Duodecim; Laaketieteellinen Aikakauskirja|August 17, 2002
[Some light for the prognosis of gastric cancer]I Elomaa, M Kouri, T Kiviluoto
Annals of Medicine|April 1, 1992
Adjuvant hormone therapy in breast cancerC P Blomqvist, I Elomaa, P Rissanen
The Journal of Urology|October 1, 1984
Five years of experience with selective therapy in recurrent calcium nephrolithiasisI Elomaa, M Ala-Opas, L Porkka
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Testicular function after chemotherapy for osteosarcomaM A Siimes, I Elomaa, A Koskimies
British Journal of Cancer|August 1, 1992
Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myelomaI Elomaa, P Virkkunen, L Risteli, et al.
Pageof 15